KR20230049579A - 암에 대해 사용하기 위한 5-아미노-8-(4-피리딜)-[1,2,4]트리아졸로[4,3-c]피리미딘-3-온 화합물 - Google Patents

암에 대해 사용하기 위한 5-아미노-8-(4-피리딜)-[1,2,4]트리아졸로[4,3-c]피리미딘-3-온 화합물 Download PDF

Info

Publication number
KR20230049579A
KR20230049579A KR1020227037221A KR20227037221A KR20230049579A KR 20230049579 A KR20230049579 A KR 20230049579A KR 1020227037221 A KR1020227037221 A KR 1020227037221A KR 20227037221 A KR20227037221 A KR 20227037221A KR 20230049579 A KR20230049579 A KR 20230049579A
Authority
KR
South Korea
Prior art keywords
methyl
amino
pyrimidin
triazolo
pyridyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227037221A
Other languages
English (en)
Korean (ko)
Inventor
길스 알버트 브라운
크리스틴 마리 리차드슨
마일스 스튜어트 콘그리브
레베카 폴
스테펜 필립 앤드류
조나단 스테펜 메이슨
Original Assignee
헵테얼즈 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 헵테얼즈 테라퓨틱스 리미티드 filed Critical 헵테얼즈 테라퓨틱스 리미티드
Publication of KR20230049579A publication Critical patent/KR20230049579A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020227037221A 2020-03-26 2021-03-25 암에 대해 사용하기 위한 5-아미노-8-(4-피리딜)-[1,2,4]트리아졸로[4,3-c]피리미딘-3-온 화합물 Ceased KR20230049579A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062994908P 2020-03-26 2020-03-26
US62/994,908 2020-03-26
PCT/EP2021/057806 WO2021191378A1 (en) 2020-03-26 2021-03-25 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer

Publications (1)

Publication Number Publication Date
KR20230049579A true KR20230049579A (ko) 2023-04-13

Family

ID=75339740

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227037221A Ceased KR20230049579A (ko) 2020-03-26 2021-03-25 암에 대해 사용하기 위한 5-아미노-8-(4-피리딜)-[1,2,4]트리아졸로[4,3-c]피리미딘-3-온 화합물

Country Status (8)

Country Link
US (1) US20230271964A1 (enExample)
EP (1) EP4126872A1 (enExample)
JP (1) JP7675094B2 (enExample)
KR (1) KR20230049579A (enExample)
CN (1) CN115867282B (enExample)
AU (1) AU2021240344A1 (enExample)
CA (1) CA3176944A1 (enExample)
WO (1) WO2021191378A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240135862A (ko) * 2022-02-01 2024-09-12 일라이 릴리 앤드 캄파니 선택적 에스트로겐 수용체 분해제의 제조 방법

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
EP2038285B1 (en) 2006-06-26 2010-02-17 Schering Corporation Adenosine a2a receptor antagonists
JP2011513417A (ja) * 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物
CN103261202B (zh) 2010-09-24 2016-01-20 阿迪维纳斯疗法有限公司 作为腺苷受体拮抗剂的稠合三环化合物
EA201792205A1 (ru) 2015-04-03 2018-02-28 Инсайт Корпорейшн Гетероциклические соединения как ингибиторы lsd1
KR20190129851A (ko) 2017-03-16 2019-11-20 지앙수 헨그루이 메디슨 컴퍼니 리미티드 헤테로아릴[4,3-c]피리미딘-5-아민 유도체, 이의 제조 방법 및 이의 의학적 용도

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240135862A (ko) * 2022-02-01 2024-09-12 일라이 릴리 앤드 캄파니 선택적 에스트로겐 수용체 분해제의 제조 방법

Also Published As

Publication number Publication date
JP7675094B2 (ja) 2025-05-12
EP4126872A1 (en) 2023-02-08
AU2021240344A1 (en) 2022-10-27
CA3176944A1 (en) 2021-09-30
CN115867282B (zh) 2025-05-27
CN115867282A (zh) 2023-03-28
US20230271964A1 (en) 2023-08-31
JP2023519362A (ja) 2023-05-10
WO2021191378A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
CN111936499B (zh) Mat2a的杂二环抑制剂和用于治疗癌症的方法
CN112513029B (zh) 含氮芳基磷氧化物类衍生物、其制备方法和应用
AU2021411587B2 (en) Indazole compounds as kinase inhibitors
TWI912127B (zh) KRas G12D抑制劑
JP6159028B2 (ja) Ｓｙｋ阻害剤
KR101862493B1 (ko) Fgfr4 억제제로서의 고리-융합된 비시클릭 피리딜 유도체
EP4305038A1 (en) Kras g12d inhibitors
KR102272792B1 (ko) Ｂｔｋ의 치환된 니코틴이미드 저해제 및 그의 제조 방법 및 암, 염증 및 자가면역 질환에의 용도
CN117957226A (zh) 作为sos1抑制剂的杂环化合物及其用途
KR20230142465A (ko) 아자퀴나졸린 범-KRas 저해제
TWI609868B (zh) 雜芳基吡啶酮及氮雜吡啶酮化合物
CN115867282B (zh) 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物
BR112021010273A2 (pt) derivados de amino triazolo quinazolina substituídos em 7, 8 e 10 como antagonistas do receptor de adenosina, composições farmacêuticas e seu uso
KR20260040007A (ko) 자가면역질환 치료를 위한 거대고리
JP7709454B2 (ja) トリアゾロン化合物
CN115867280B (zh) 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物
WO2024220399A1 (en) Pyrazolotriazinecarbonitriles useful as kinase inhibitors
TW202504586A (zh) 治療發炎性疾病之方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601